1. Introduction {#sec1-pathogens-09-00601}
===============

*Strongyloides stercoralis* is an intestinal helminth acquired by humans when larvae penetrate intact skin following contact with infected soil \[[@B1-pathogens-09-00601]\]. It has a peculiar autoinfection life cycle that may lead to lifelong chronic infection if left untreated. Its clinical spectrum can range from cutaneous (pruritus, larva currens, urticaria), digestive (diarrhea, abdominal pain), or respiratory (chronic cough, dyspnea) symptoms to asymptomatic eosinophilia or even silent infections, which constitute the vast majority of infections in endemic areas \[[@B2-pathogens-09-00601],[@B3-pathogens-09-00601]\].

On occasion, it manifests as a life-threatening complication with the development of hyperinfection syndrome. While initially confined to the lungs and the gastrointestinal tract, it has signs and symptoms of severe disease due to an elevated number of larvae. With time, this syndrome can progress toward a disseminated strongyloidiasis, which is the most severe form, when larvae might be found in any organ, not just in the respiratory or gastrointestinal tract. Both the hyperinfection and disseminated forms are particularly common in immunosuppressed patients, such as those with hematological malignancies, those with human T-lymphotropic virus type 1 (HTLV-1) infection, transplant recipients, and those receiving immunosuppressive treatments (especially corticosteroids) \[[@B1-pathogens-09-00601],[@B4-pathogens-09-00601]\].

Strongyloidiasis is prevalent globally, with an estimated 30 million to 370 million infected people worldwide \[[@B5-pathogens-09-00601]\]. Although it generally occurs in tropical and subtropical regions, sporadic cases have been reported in temperate countries \[[@B6-pathogens-09-00601]\]. Despite its high prevalence, it has not been well studied. Furthermore, its prevalence may be underestimated due to the lack of a gold standard diagnostic test \[[@B4-pathogens-09-00601],[@B7-pathogens-09-00601]\].

In Spain, increased migratory flows have driven recent increases in imported cases \[[@B8-pathogens-09-00601]\]. Prevalence amongst immigrants is variable, ranging from 4.5% to 17% in studies done in referral units but up to 36% in people coming from Cambodia or 10% to 27% in those from Latin America \[[@B9-pathogens-09-00601],[@B10-pathogens-09-00601]\].

Autochthonous cases also occur in Spain, especially in the Mediterranean basin (Valencian region and Murcia). The vast majority are restricted to a specific area of La Safor and Marina Alta regions, corresponding to Health Area 11 of the Valencian Community \[[@B11-pathogens-09-00601],[@B12-pathogens-09-00601]\]. In these areas, prevalence is 0.3% in the general population and 12.4% in high-risk groups, mostly men aged over 50 who participate in agricultural activities \[[@B13-pathogens-09-00601]\]. A combination of adequate temperature and humidity, lack of hygiene in rural areas during the 1960s, and a population exposed to *S*. *stercoralis* for occupational reasons (such as rice farmers or irrigation ditch cleaners) may have facilitated a concentration of cases in that particular area. A greater awareness of strongyloidiasis among health care workers of that department may have contributed as well \[[@B14-pathogens-09-00601]\]. Outside this region, only a few isolated autochthonous cases have been reported, most of which have been based only on serological diagnosis \[[@B14-pathogens-09-00601],[@B15-pathogens-09-00601],[@B16-pathogens-09-00601],[@B17-pathogens-09-00601]\]. In light of these limited case numbers, Spain is not considered an endemic country for strongyloidiasis \[[@B18-pathogens-09-00601]\].

Vega Baja del Segura is a region located in southern Alicante, near the border with Murcia, where some isolated cases have been reported \[[@B19-pathogens-09-00601]\]. In a previous study, our group retrospectively reviewed the cases of autochthonous strongyloidiasis at the Vega Baja Hospital in Orihuela between January 1999 and March 2016, finding 10 autochthonous cases in that period \[[@B20-pathogens-09-00601]\].

Our region thus offers unique opportunities for strongyloidiasis research, allowing comparisons between imported and autochthonous cases. The aim of this study was to analyze the clinical, epidemiological, and microbiological characteristics of all patients diagnosed with strongyloidiasis at the Vega Baja Hospital between 1999 and 2019 and to compare autochthonous versus imported cases.

2. Results {#sec2-pathogens-09-00601}
==========

Between January 1999 and January 2019, 36 patients (21 men, 58%), with a mean age of 60.81 ± 17.57 years, were diagnosed with strongyloidiasis at the Vega Baja Hospital. There were 15 autochthonous and 21 imported cases ([Figure 1](#pathogens-09-00601-f001){ref-type="fig"}).

Eighteen of the imported cases came from Latin America (1 Dominican Republic, 1 Ecuador, 1 Colombia, 12 Bolivia, 1 Jamaica, and 1 English woman who frequently travelled to the Caribbean) and 4 from Africa (3 Morocco and 1 Spanish long-term resident in Algeria). The geographic distribution of autochthonous and imported patients according to the municipality of residence in the Vega Baja del Segura region is shown in [Figure 2](#pathogens-09-00601-f002){ref-type="fig"}.

Twenty-two cases (61.1%) were symptomatic at the time of diagnosis, most of them (n = 9) with mild digestive symptoms such as diarrhea and abdominal pain, followed by pruritus (n = 3) and respiratory symptoms (n = 2). Two autochthonous cases had a hyperinfection syndrome, and one had disseminated strongyloidiasis; all had been treated with corticosteroids prescribed for different comorbidities (two for chronic obstructive pulmonary disease and one for lung cancer); two died.

Six patients (16.7%) had a neoplasia (two bladder tumors, one lung adenocarcinoma, one colon adenocarcinoma, one meningioma, and one non-Hodgkin's lymphoma), and three patients (8.3%) had chronic obstructive pulmonary disease. Ten patients (27.8%) were co-infected with *Trypanosoma cruzi* and one patient with hydatidosis. Twenty-nine patients were serologically tested for HIV, all with negative results, and only five (two autochthonous and three imported) were tested for human T cell lymphotropic virus 1 (HTLV-1), also with negative results. Five patients were treated with corticosteroids at the time of diagnosis (26.7% autochthonous vs. 4.8% imported). [Table 1](#pathogens-09-00601-t001){ref-type="table"} shows the comparative analysis between autochthonous and imported patients.

Eosinophilia at diagnosis was detected in 29 patients (80.6%): in 14 (93.3%) of the autochthonous cases and 16 (75%) of the imported ones, with an average eosinophil count of 1200 ± 870 eosinophils/mm^3^. *Strongyloides* serology was performed in 34 patients (94.4%) and was positive in all of them; 22 cases (64.7%) had a serological index greater than 2.5 (12 imported and 10 autochthonous). *Strongyloides* stool culture was performed in 20 patients (55.5%) and was positive in three. In four patients, the diagnosis was made by visualization of larvae in a biopsy, in one by duodenal aspirate culture, and in another one by sputum culture.

Twenty-seven patients were treated with ivermectin (24 with double dose two weeks apart, 2 with a 7-day course, and 1 with a 14-day course), three with ivermectin plus albendazole, one with albendazole, and one with thiabendazole. Four (11%) patients died, and three (8%) had a therapeutic failure and were treated again (two autochthonous and one imported case). The two autochthonous cases with therapeutic failure were immunosuppressed patients: one was treated initially with ivermectin double dose and after failure with ivermectin plus albendazole for seven days, and the other one with ivermectin double dose in both occasions. The imported case with therapeutic failure was not immunosuppressed and was treated on both occasions with ivermectin double dose. [Table 2](#pathogens-09-00601-t002){ref-type="table"} and [Table 3](#pathogens-09-00601-t003){ref-type="table"} summarize the clinicoepidemiological characteristics of autochthonous and imported cases.

3. Discussion {#sec3-pathogens-09-00601}
=============

In Spain, autochthonous cases of strongyloidiasis are concentrated in the Mediterranean basin, namely in the autonomous regions of Valencia and Murcia, where autochthonous cases coexist with imported strongyloidiasis. In our region, autochthonous cases are predominantly in men and appear in people who are older compared to those with imported cases. Agricultural activities, whether for work or for leisure, were also associated with autochthonous cases. The sociodemographic characteristics of our autochthonous patients are similar to those described in previous studies in the Valencian region \[[@B13-pathogens-09-00601],[@B20-pathogens-09-00601]\]. Moreover, a recent systematic review of autochthonous cases \[[@B21-pathogens-09-00601]\] of strongyloidiasis in Spain also reports a high percentage of men (82.9%), agricultural occupations, and a mean age of 68.3 years. The predominance of men among the autochthonous cases seems to be linked to the mode of acquisition, in most cases occupational. On the other hand, there are some studies in experimental animal models \[[@B22-pathogens-09-00601]\] that describe a greater susceptibility to *Strongyloides* in male rats, attributed to the protective effect of estrogen and the immunosuppressive role of androgens. Autochthonous patients had a mean age of 71.3 ± 16.2 years; if screening of the autochthonous population is considered, the target population should include at least people aged over 55 years.

In our study we found a higher percentage of symptomatic patients among autochthonous cases, although this result was not statistically significant. This may be due to a lower rate of suspicion in autochthonous patients, who are often diagnosed after presenting symptoms, while immigrants are more frequently screened opportunistically in clinical settings or in community screening campaigns for Chagas disease \[[@B23-pathogens-09-00601]\]. Likewise, the only three cases of hyperinfection syndrome occurred in autochthonous cases. Patients with autochthonous strongyloidiasis also had more comorbidities and more risk factors for hyperinfection (especially corticosteroid treatment).

In our study, as in others \[[@B12-pathogens-09-00601],[@B24-pathogens-09-00601],[@B25-pathogens-09-00601]\], the prevalence of eosinophilia was high in both groups, representing a good indicator of infection. However, restricting the screening to people with eosinophilia could result in missed cases, especially in patients already on corticosteroid treatment in whom eosinophilia may be more frequently absent.

Regarding strongyloidiasis diagnosis, the main problem is the low sensitivity of traditional diagnostic methods and the absence of a gold standard. The sensitivity of techniques for detecting rhabditiform larvae in feces does not exceed 40%, due primarily to the intermittent pattern of excretion \[[@B5-pathogens-09-00601]\]. Agar plate culture of *Strongyloides* larvae increases the sensitivity to some extent, but it remains under 60% in single samples. Serology (IgG for filariform larvae) has a better sensitivity (83--89%) and is considered the best technique to screen asymptomatic immigrants and monitor treatment effectiveness. A recent study on the diagnostic accuracy of serological tests for *S. stercoralis* reported high sensitivity (91.2%) and specificity (99.1%) for IVD-ELISA \[[@B26-pathogens-09-00601]\]. However, another study in immunosuppressed patients showed a sensitivity of just 42.9%, with a specificity of 96.3% \[[@B27-pathogens-09-00601]\]. The latest guidelines for the management of strongyloidiasis in non-endemic countries recommend a combination of serological and parasitological techniques in immunosuppressed patients \[[@B28-pathogens-09-00601]\]. Serology can yield false positives, mainly by cross-reaction with other helminths; however, a recent study shows that increasing the optical density index (OD)index cutoff to 2.5 can increase specificity to almost 100% \[[@B26-pathogens-09-00601]\]. Applying this cutoff to our series would result in 26 cases: 22 cases diagnosed by serology (12 imported and 10 autochthonous), plus 4 cases with parasitological diagnosis and no serology available. The use of *Strongyloides* RT-PCR in feces seemed promising in early studies, with sensitivity above 90% \[[@B29-pathogens-09-00601]\], but it has not proven to add much value to serology. A recent meta-analysis reports a PCR sensitivity of 56.5% to 71.8% and concludes that further studies are needed to determine its real diagnostic utility \[[@B4-pathogens-09-00601]\].

Regarding treatment, in our series most cases were treated with ivermectin, with high efficacy rates and excellent tolerability. No statistically significant differences were observed between autochthonous versus imported cases regarding treatment or treatment response (response 85.7% vs. 88.9%; *p* = 1). These cure rates are very similar to those described in the Strong--Treat study, which compared the efficacy of a single dose of ivermectin versus a four-dose regimen, reporting an efficacy of 86% for the single-dose regimen \[[@B30-pathogens-09-00601]\]. Three patients required retreatment for therapeutic failure, two autochthonous and one imported.

In the municipality of Oliva (Valencia province), one study estimated seroprevalence at 0.9%, with authors concluding that there is probably no active transmission at present given the absence of cases in young people and the changes in agricultural practices \[[@B13-pathogens-09-00601]\]. The systematic review of endemic cases in Spain \[[@B22-pathogens-09-00601]\] showed a decrease in the number of cases reported since 2011. However, in our series, most cases were diagnosed in recent years. This seems to be due to a higher rate of suspicion among professionals in the area following several educational activities about the existence of autochthonous cases in the health department. Although our patients' characteristics are similar to those from Oliva, we cannot categorically state that there is no active transmission in our area. In our opinion, large seroprevalence studies and field studies searching for larvae would be needed to rule out active transmission.

Given the potential severity of strongyloidiasis in immunosuppressed individuals, we believe it is essential to implement a strongyloidiasis screening protocol in our area, both in immigrants from and travelers to endemic areas \[[@B28-pathogens-09-00601]\], along with autochthonous people with risk factors, especially those who are becoming immunosuppressed. A recent cost-effectiveness study of strongyloidiasis screening in immigrant populations \[[@B31-pathogens-09-00601]\] in Europe concluded that prophylactic administration of ivermectin is cost-saving in patients from strongyloidiasis-endemic countries and at risk of immunosuppression. However, additional studies are needed on whether different screening strategies in autochthonous populations could be more cost-effective than prophylactic treatment.

The present study has several limitations. First, since our setting has sporadic cases of strongyloidiasis, we cannot rule out that some cases in long-term residents of the Vega Baja del Segura area were misclassified as imported. Another limitation of our study is the use of different diagnostic methods over time and the fact that in a significant percentage of cases, diagnosis was exclusively serological. Besides, Latin American countries are endemic for HIV and HTLV-1 virus. HTLV-1 infection is a well-known factor for strongyloidiasis hyperinfection syndrome \[[@B32-pathogens-09-00601]\]. However, information about HTLV-1 serostatus of our patients was limited as serology was not routinely requested. Furthermore, the study's retrospective nature means that case follow-up was not standardized, and treatment response has been assessed at different times. Serology is a frequently used response marker that has proven useful in several studies, including in immunosuppressed individuals \[[@B33-pathogens-09-00601],[@B34-pathogens-09-00601]\].

4. Materials and Methods {#sec4-pathogens-09-00601}
========================

Observational retrospective study in all patients diagnosed with strongyloidiasis at the Vega Baja Hospital (Orihuela) from January 2009 to January 2019 was used. The Orihuela health department has a population of 167,415 inhabitants (33.43% foreigners) \[[@B35-pathogens-09-00601]\]. We included all cases with histopathological diagnosis (visualization of *Strongyloides* larvae in intestinal biopsy; [Figure 3](#pathogens-09-00601-f003){ref-type="fig"}), parasitological diagnosis (either by visualization of larvae in fresh stool or after fecal culture, of duodenal aspirate, or other samples), or serological diagnosis (positive for IgG antibodies to *Strongyloides*). The serological study was carried out at the Spanish National Centre for Microbiology, Instituto Nacional de Salud Carlos III Majadahonda, Madrid. The serological study was carried out at the National Centre of Microbiology using a non-automated IVD-ELISA technique that detects IgG antibodies against raw antigen of filariform larvae (DRG Instruments Gmbh, Marburg, Germany), with a positive optical density index (OD) cutoff of 1.1. Coproparasitological and fecal culture were performed at the microbiology laboratory of the Vega Baja Hospital. Stool concentration was performed using the Mini Parasep SF Alcorfix system. *Strongyloides* culture was seeded in Mueller Hinton agar, incubated at 28 °C, and observed for five days in search of the sinuous trajectories. We considered cases autochthonous if they were in patients who had resided in the Vega Baja region for more than 30 years and had never traveled to a *Strongyloides*-endemic area, while cases were defined as imported if they were in immigrants from or travelers to endemic areas. Chronic corticosteroid treatment was defined as at least 20mg per day of prednisone for ≥14 days.

During the study period, three Chagas disease and *Strongyloides* community screening campaigns among Latin American immigrants were performed at our province, in 2016, 2017, and 2018.

Demographic, clinical, analytical, microbiological, and treatment-related variables were recorded for included patients, and their most recent status (up to 31 January 2019) was reviewed. Eosinophilia was defined as an eosinophil count exceeding 500 eosinophils/mm^3^; serological response was defined as seroreversion or post-treatment/pre-treatment OD of less than 0.6.

The analysis was performed using SPSS v. 23.0 (SPSS statistics for Windows, version 23.0, Armonk, NY, USA). The one-sample Kolmogorov Smirnov test was used to assess the distribution of continuous variables, and the Student t-test to compare them between groups. The chi-squared test or Fisher's exact test were used, as appropriate, to compare qualitative variables.

5. Conclusions {#sec5-pathogens-09-00601}
==============

Autochthonous and imported cases of strongyloidiasis coexist in our region, and diagnosis of the disease has increased in recent years. Autochthonous cases occur mainly in older men who take part in agricultural activities, and they tend to be diagnosed in more advanced stages. Increased clinical suspicion of this entity is warranted, as are screening programs for both autochthonous populations and immigrants from endemic areas. Screening could decrease the diagnostic delay and thus avoid the potential development of hyperinfection syndrome.
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pathogens-09-00601-t001_Table 1

###### 

Comparative analysis between autochthonous and imported strongyloidiasis cases at Vega Baja Hospital.

  Variables                              Autochthonous (N = 15)   Imported (N = 21)   *p*           OR (95% CI)
  -------------------------------------- ------------------------ ------------------- ------------- --------------------
  Median age, in years                   71.33                    53.29               *p* = 0.002   
  Men                                    12 (80%)                 9 (43%)             *p* = 0.041   5.33 (1.15--24.68)
  Agriculture dedication                 10 (69.2%)               3 (14.3%)           *p* = 0.002   13.5 (2.4--73.7)
  Symptomatic patients                   11 (73.3%)               11 (52.4%)          *p* = 0.302   0.4 (0.75--2.12)
  Corticosteroid treatment               4 (26.7%)                1 (4.8%)            *p* = 0.138   5.77 (0.55--60.60)
  Eosinophilia                           14 (93.3%)               16 (75.5%)          *p* = 0.207   4.66 (0.48--45.04)
  Response to treatment                  13 (85.7%)               19 (88.9%)          *p* = 1       3.20 (0.22--45.19)
  Hyperinfection syndrome                3 (20%)                  0 (0%)              *p* = 0.064   0.80 (0.61--1.03)
  Death attributed to strongyloidiasis   2 (13.3%)                0 (0%)              *p* = 0.167   0.86 (0.71--1.05)

OR: odds ratio; CI: confidence interval.

pathogens-09-00601-t002_Table 2

###### 

Clinicoepidemiological characteristics of autochthonous strongyloidiasis cases at Vega Baja Hospital.

  Case   Sex, Age in Years   Date of Diagnosis   Occupation   Comorbidities and Risk Factors              Clinical Manifestations                    Eosinophilia (Eosinophils/mm^3^)   Method of Diagnosis (in Serology, Optical Density Index)              Strongyloidiasis Treatment   Outcome
  ------ ------------------- ------------------- ------------ ------------------------------------------- ------------------------------------------ ---------------------------------- --------------------------------------------------------------------- ---------------------------- ----------------------------------------
  1      M, 69               July 2007           Farmer       Lung cancer Chemotherapy and radiotherapy   Hemoptysis, Hyperinfection syndrome        Yes (600)                          Larvae in sputum Serology not requested                               None                         Death
  2      M, 72               March 2015          Shipper      COPD, Corticosteroids                       Hyperinfection syndrome                    Yes (2400)                         Larvae in large intestine biopsy and fecal samples Serology +(8.88)   Ivermectin + albendazole     Death
  3      F, 73               May 2015            Farmer       Diverticulosis                              Digestive                                  Yes (2700)                         Serology +(1.93)                                                      Ivermectin + albendazole     Recovery
  4      M, 80               December 2015       Farmer       Bladder cancer                              Digestive, Skin                            Yes (700)                          Serology +(4.45)                                                      Ivermectin                   Seroreversion
  5      M, 85               May 2016            Farmer       Biliary disease Low-grade lymphoma          Digestive                                  Yes (570)                          Serology +(6.83)                                                      Ivermectin                   Re-treatment (ivermectin)
  6      M, 79               June 2016           Unknown      None                                        Digestive                                  No                                 Serology +(3.15)                                                      Ivermectin                   Re-treatment (ivermectin +albendazole)
  7      M, 71               November 2016       Gardener     Colon adenocarcinoma                        Asymptomatic                               Yes (2400)                         Larvae in large intestine biopsy and fecal samples Serology +(8.88)   Ivermectin                   Seroreversion
  8      M, 80               March 2017          Farmer       COPD, Atrial fibrillation Diabetes          Disseminated Strongyloidiasis Meningitis   Yes (640)                          Larvae in fecal cultures and fresh fecal samples. Serology +(1.16)    Ivermectin                   Seroreversion
  9      M, 83               May 2017            Farmer       Prolactinoma, Diabetes                      Asymptomatic                               Yes (1450)                         Serology +(6.85)                                                      Ivermectin                   Dead (surgery)
  10     F, 49               January 2018        Unknown      Rheumatoid arthritis                        Asymptomatic                               Yes (780)                          Serology +(1.35)                                                      None                         Lost to follow-up
  11     M, 74               May 2018            Farmer       Renal insufficiency                         Skin                                       Yes (900)                          Serology +(3.41)                                                      Ivermectin                   Seroreversion
  12     F, 25               June 2018           Unknown      None                                        Asymptomatic                               Yes (810)                          Serology +(1.32)                                                      None                         Lost to follow-up
  13     M, 89               June 2018           Farmer       Hypereosinophilic syndrome                  Skin                                       Yes (1700)                         Serology +(14.35)                                                     None                         Dead
  14     M, 80               January 2019        Unknown      None                                        Asymptomatic                               Yes (1660)                         Serology +(10.10)                                                     Albendazole                  Seroreversion
  15     M, 61               January 2019        Printer      Gastroesophageal reflux                     Digestive                                  Yes (510)                          Serology +(2.90)                                                      Ivermectin                   Seroreversion

COPD: Chronic obstructive pulmonary disease.

pathogens-09-00601-t003_Table 3

###### 

Clinicoepidemiological characteristics of imported strongyloidiasis cases at Vega Baja Hospital.

  Case   Sex, Age in Years   Date of Diagnosis   Country of Case Origin   Occupation            Comorbidities and Risk Factors           Clinical Manifestations   Eosinophilia (Eosinophils/mm^3^)   Method of Diagnosis (in Serology, Optical Density Index)                    Strongyloidiasis Treatment   Outcome
  ------ ------------------- ------------------- ------------------------ --------------------- ---------------------------------------- ------------------------- ---------------------------------- --------------------------------------------------------------------------- ---------------------------- ---------------------------
  1      M, 70               May 1999            Algeria                  Unknown               Bladder cancer, asthma Corticosteroids   Digestive                 Yes (670)                          Larvae in duodenal biopsy; serology not requested                           Thiabendazole                Lost to follow-up
  2      F, 80               August 2011         Dominican Republic       Housekeeper           None                                     Digestive                 Yes (3000)                         Larvae in fresh stool samples and duodenal fluid; serology result unknown   Ivermectin                   Clinical recovery
  3      F, 78               July 2015           UK                       Salesperson           COPD                                     Digestive                 No                                 Serology +(1.73)                                                            Ivermectin                   Lost to follow-up
  4      M, 57               September 2015      Ecuador                  Metallurgy            Biliary disease                          Digestive                 Yes (1000)                         Serology +(3.33)                                                            None                         Lost to follow-up
  5      M, 38               November 2015       Bolivia                  Farmer                Chagas                                   Asymptomatic              No (140)                           Serology +(1.67)                                                            Ivermectin                   Lost to follow-up
  6      M, 51               December 2015       Bolivia                  Construction worker   Chagas                                   Asymptomatic              Yes (1300)                         Serology +(13.33)                                                           Ivermectin                   Serological response
  7      M, 52               January 2016        Bolivia                  Unknown               Chagas                                   Asymptomatic              Yes (1390)                         Serology +(13.73)                                                           Ivermectin                   Serological response
  8      M, 52               March 2016          Bolivia                  Farmer                Chagas                                   Asymptomatic              Yes (880)                          Larvae in duodenal biopsy; Serology +(15.86)                                Ivermectin                   Serological response
  9      M, 48               May 2016            Bolivia                  Construction worker   Chagas                                   Digestive                 Yes (830)                          Serology +(7.54)                                                            Ivermectin                   Seroreversion
  10     F, 50               December 2016       Bolivia                  Caregiver             Chagas                                   Digestive                 No (320)                           Serology +(7.92)                                                            Ivermectin                   Seroreversion
  11     F, 35               June 2016           Bolivia                  Unknown               None                                     Asymptomatic              Unknown                            Serology +(14.16)                                                           Ivermectin                   Serological response
  12     F, 50               July 2016           Bolivia                  Unknown               Chagas                                   Asymptomatic              Yes (750)                          Serology +(6.71)                                                            Ivermectin                   Seroreversion
  13     F, 80               October 2016        Jamaica                  Nurse                 Unknown                                  Digestive                 Yes (1100)                         Serology +(2.37)                                                            Ivermectin                   Seroreversion
  14     F, 37               March 2017          Bolivia                  Farmer                None                                     Digestive                 Yes (1000)                         Serology +(5.19)                                                            Ivermectin                   Re-treatment (ivermectin)
  15     M, 68               July 2017           Colombia                 Unknown               None                                     Asymptomatic              Yes (1300)                         Serology +(1.85)                                                            Ivermectin                   Seroreversion
  16     F, 44               February 2018       Morocco                  Unknown               Meningioma                               Asymptomatic              Unknown                            Serology +(1.30)                                                            Ivermectin                   Lost to follow-up
  17     F, 58               June 2018           Bolivia                  Housekeeper           Chagas                                   Digestive                 Yes (700)                          Serology +(4.82)                                                            Ivermectin                   Seroreversion
  18     F, 40               September 2018      Bolivia                  Unknown               Chagas                                   Asymptomatic              Unknown                            Serology +(1.15)                                                            Ivermectin                   Lost to follow-up
  19     F, 57               October 2018        Bolivia                  Housekeeper           Chagas                                   Asymptomatic              Yes (990)                          Serology +(6.83)                                                            Ivermectin                   Seroreversion
  20     F, 37               December 2018       Morocco                  Unknown               Hydatidosis                              Respiratory               Yes (3960)                         Serology +(2.66)                                                            Ivermectin                   Seroreversion
  21     M, 37               January 2019        Morocco                  Shopkeeper            None                                     Asymptomatic              Yes (510)                          Serology +(2.36)                                                            Ivermectin                   Lost to follow-up

COPD: chronic obstructive pulmonary disease.
